Evidence map›Paper›PMID 32170592›Full record

ReviewBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2020

Lysine acetylation as drug target in fungi: an underexplored potential in Aspergillus spp.

Natália Sayuri Wassano, Ariely Barbosa Leite, Franqueline Reichert-Lima, Angelica Zaninelli Schreiber, Nilmar S Moretti, André Damasio

Open access · greenAbstract readReview
In one paragraph

Review in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Genotype-Phenotype Relationships in Azole-ResistantJournal of fungi (Basel, Switzerland) · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Natália Sayuri WassanoDepartment of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, SP, Brazil.
Ariely Barbosa LeiteDepartment of Microbiology, Immunology and Parasitology, Escola Paulista de Medicina, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil.
Franqueline Reichert-LimaDepartment of Clinical Pathology, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, SP, Brazil.
Angelica Zaninelli SchreiberDepartment of Clinical Pathology, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, SP, Brazil.
Nilmar S MorettiDepartment of Microbiology, Immunology and Parasitology, Escola Paulista de Medicina, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil. nilmar.moretti@unifesp.br.
André DamasioDepartment of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, SP, Brazil. adamasio@unicamp.br.
Universidade Estadual de Campinas (UNICAMP) · BRUniversidade Federal de São Paulo · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) 123313/2018-0Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) 304816/2017-5Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) 404654/2018-5Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) 424729/2018-0São Paulo Research Foundation (FAPESP) 2017/22669-0São Paulo Research Foundation (FAPESP) 2018/09948-0
6 · The paper itself

Abstract

In recent years, the intensification of the use of immunosuppressive therapies has increased the incidence of invasive infections caused by opportunistic fungi. Considering that, the spread of azole resistance and amphotericin B (AmB) inefficiency against some clinical and environmental isolates has been described. Thus, to avoid a global problem when controlling fungal infections and critical failures in medicine, and food security, new approaches for drug target identification and for the development of new treatments that are more effective against pathogenic fungi are desired. Recent studies indicate that protein acetylation is present in hundreds of proteins of different cellular compartments and is involved in several biological processes, i.e., metabolism, translation, gene expression regulation, and oxidative stress response, from prokaryotes and eukaryotes, including fungi, demonstrating that lysine acetylation plays an important role in essential mechanisms. Lysine acetyltransferases (KATs) and lysine deacetylases (KDACs), the two enzyme families responsible for regulating protein acetylation levels, have been explored as drug targets for the treatment of several human diseases and infections. Aspergilli have on average 8 KAT genes and 11 KDAC genes in their genomes. This review aims to summarize the available knowledge about Aspergillus spp. azole resistance mechanisms and the role of lysine acetylation in the control of biological processes in fungi. We also want to discuss the lysine acetylation as a potential target for fungal infection treatment and drug target discovery.

Indexed as

AcetylationAspergillosisAspergillusDrug DiscoveryHumansLysinePharmaceutical PreparationsProtein Processing, Post-TranslationalLysinePharmaceutical PreparationsAspergillus spp.Drug resistanceKATsKDACsLysine acetylation

Identifiers

PMID32170592
PMCPMC7203240
OpenAlexW3010840732

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.